Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma.

ABSTRACT:

Introduction

ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information.

Objective

Here, we report a next generation sequencing (NGS)-based assay for predicting the prenatal ABO blood group.

Materials and methods

A total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-fr

SUBMITTER: Rieneck K 

PROVIDER: S-EPMC7036558 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature